äžçã®å¶Öçµçæ³åŸºå ŽèŠæš¡ã¯ã2021 幎㫠63 å 6,000 äžç±³ãã«ãšè©äŸ¡ããã¶Ä 2030 幎ãŸã§ã« 118 å 5,000 äžç±³ãã«ã«éãããšäºæž¬ãããŠããã2022 幎ãã 2030 幎ã«ãããŠ7.16% ã® CAGR ãèšé²ããŸãã¶Ä
å¯å·çæ³ãŸãã¯ã¢ã€ã¹ããã¯çæ³ãšããŠãç¥ãããå¶Öçµçæ³ã¯ãããŸããŸãªçµç¹ãç¥çµã®ç å€ãç Žå£ããåå®®é žãããç¶²èèœçްèÓÅè «ã¶Äç®èãããªã©ã®ç æ°ãæ²»çÉ¡ãããã«äœ¿çšãããŸããå¶Öçµçæ³ã¯ãå·åŽçæ³ãŸãã¯ã¢ã€ã¹ããã¯çæ³ãšããŠãç¥ãããŠããŸãã¶Äæ£Ô¿ ã¯ãé·æéã®éåã¶ÄçÏâã®æ»æ«ããŸãã¯ãã®ä»ã®çš®é¡ã®çµç¹æå·ã®çµæãšããŠç·åŒµãŸãã¯æå·ããäœã®éšåã軜æžãããªã©ãã¯ã¹ãããããã«æ°·æµŽã嵯ããŸãã¶Ä±žœæž©ã«ããè¡¶Ä管ãåçž®ãã¶Äãã®é åã«å°éããÁÍçžä§ãµã€ãã«ã€ã³ã®æ°ãæžå°ãã¶ÄçµæãšããŠçã¿ã®åŒ·åºŠãå€§å¹ ã«å¢å ããŸãã
åçµçæ³æ²»çã§ã¯ãã¢ã«ãŽã³ãçªçŽ ãªã©ã®ããŸããŸãªã¬ã¹ã䜿çšãããŸãã¶Äå¶ÖçµãããŒãã¯ãçã«ãã£ãŠåŒãèµ·ããããåÊŠçºè «çãÕòªæ¶Ä§è «çãæ²»çããããã«ã¶Ääœã®æšçé åã«æ¶²äœçªçŽ ãçŽæ¥é¶Äéããããã«äœ¿çšãããŸãã¶Äå¶Öçµæ×¹è¡ã«ã¯ã¶ÄåŸæ¥ã®æè¡ãã㱞žå¿«æãå°ãªãããšã䟵襲æ¶Ä§ãäœãæ¹æ³ã§å®è¡ãããããšãææÆËÉðæã®å¯èœžä§ãäœããªããããè¿ éãªå埩ã䌚é²ãããããšãªã©ãå€ãã®å©ç¹ããããŸãã¶Ä
ã¬ããŒãææš | 詳现 |
---|---|
åºæºå¹Ž | 2021 |
Áç©¶ÁŽé | 2020-2030 |
äºæ³ÁŽé | 2025-2033 |
幎平åæé·ç | 7.16% |
Äþå ŽèŠæš¡ | 2021 |
žä¥æé·åŸºå Ž | ã¢ãžã¢å€ªå¹³æŽå°åÑÌ |
Á޶Äå€§åŸºå Ž | åç±³ |
ã¬ããŒãç¯å² | åçäºæž¬ãç«¶åç°å¢ã¶Äæé·èŠå ã¶Äç°å¢ïÉŽã©ã³ãã¶ÄèŠå¶æ å¢ãšåå |
察象å°åÑÌ |
|
é·å¹Žã«ãããæ°å€ãã®æè¡é²æ©ãšåçµçæ³è£ 眮ã®é²æ©ã«ãããåçµçæ³ã¯éèŠãªæ²»çéžæè¢ãšãªã£ãŠããŸããå·åæè¡ã®æ©æ¢°ãä»å±åãªã©ãããŸããŸãªæ©åšãé²åããŠããŸãããççãé¢ç¯ãªãŠãããçŒç管çãäžè¬çãªçŸå®¹ããã³å¥åº·çæ³ã®æ²»çã«äžè¬çã«äœ¿çšãããå·å¶Öãã£ã³ããŒãšå·å¶ÖãµãŠããã倧ããªé²æ©ãéããŠããŸããããã«ãå·åæè¡è£ 眮ã¯ãå·åŽã®ããã®éå·åŽæ¶²äœçªçŽ ãŸãã¯ä»ã®å¯å€ã®äœ¿çšãããŸããŸãªãµã€ãºã§å©çšå¯èœãªèããŠå¹ççãªãããŒãã®å°å ¥ã现ã匷åãããå·åã¢ãã¬ãŒã·ã§ã³éã®é©çšãªã©ãããªãã®é²æ©ãéããŠããŸããããšãã°ã2018 幎 9 æã« Galil Medical ã¯ãå瀟㮠Visual ICE ãã¯ãããžãŒã®ã¢ããã°ã¬ãŒãã§ãã ICEfx å·åã¢ãã¬ãŒã·ã§ã³ ã·ã¹ãã ãå°å ¥ããŸãããæ°ãããã¯ãããžãŒã«ã¯ãããªãŠã ããªãŒè§£åæ©èœãåããã¢ããã°ã¬ãŒããããããŒãã« ãã©ãããã©ãŒã ããããè§£åæéãççž®ããããªãŠã ã®ã³ã¹ããåæžããŸããããã«ãããŒã¿ãã«ã§è¿ éãªå°å ¥ãå¯èœã§ããŠãŒã¶ãŒãã¬ã³ããªãŒãªç»é¢äžã®ã¬ã€ãã³ã¹ã«ãã£ãŠæäœãåçåãããŸãã
補åã®çºå£²ã®å¢å ãæé ãªäŸ¡æ Œã®åçµçæ³è£ 眮ãããã³åçµçæ³è£ 眮ã®äœ¿çšã®å¢å ããäºæž¬æéå šäœãéããŠåžå Žã®æ¡å€§ãä¿é²ãããšäºæ³ãããŸããããšãã°ãå šèº«åçµçæ³ã·ã¹ãã ã®ã¡ãŒã«ãŒã§ãã CryoBuilt, Inc. ã¯ã2020 幎 5 æã«ãæå ç«¯ã§æé ãªäŸ¡æ Œã®å šèº«åçµçæ³ãã£ã³ã㌠ã·ãªãŒãºã§ãã EVEREST ãå°å ¥ããŸãããEVEREST ãã£ã³ããŒã¯ãæå®³ãªã¬ã¹ã«ãããããããšãªãããã£ã³ããŒãå·åŽããŸããå·ããæ°é®®ãªé žçŽ ãå«ãã 空æ°ãšãšãã«ãå瀟㮠CryoBrain ã¢ããªã䜿çšãããšãCryoBuilt, Inc. ã® EVEREST ã·ãªãŒãºã®ãã£ã³ããŒã®ãŠãŒã¶ãŒã¯ã·ã¹ãã ãå®å šã«æäœã§ããŸãã
æ¥µäœæž©ã¬ã¹ã«äŒŽãÑÇÕòªåœ±À«¿ã¯ãæ¥çã®æ¡å€§ã劚ããéèŠãªèŠçŽ ã§ããåçµçæ³ã¯ãçªçŽ ãããªãŠã ãããªã³ãã¢ã«ãŽã³ãæ°ŽçŽ ãã¡ã¿ã³ãæ¶²å倩ç¶ã¬ã¹ãªã©ã倿°ã®ã¬ã¹ã®æ··åç©ã䜿çšããæ²»çæ³ã§ãããã®æ²»çã¯æ£è ã®å¥åº·ã«ããŸããŸãªæªåœ±é¿ãåãŒãå¯èœæ§ããããŸããæ¥µäœæž©ã®æ¶²äœãšãããã«é¢é£ããå·ããèžæ°ãã¬ã¹ããç®èã«ã¢ã¬ã«ã®ãŒæ§ã®æªåœ±é¿ãåŒãèµ·ããå¯èœæ§ããããŸããåå·ãããç¶ã®ç®èã®åºçŸã¯ã極床ã®äœæž©ã§ç®èã«é·æéãããããããæ°·ã®è¡šé¢ã«æ¥è§Šãããããããšã«ãã£ãŠåŒãèµ·ããããããšããããŸããããã«ãã¡ã¿ã³ãæ°ŽçŽ ãäžé žåççŽ ãæ¶²å倩ç¶ã¬ã¹ãªã©ã®å¯çæ§ã¬ã¹ã¯æ¥æ¿ã«èšåŒµããç«çœãççºãªã©ã®å±éºãåŒãèµ·ããå¯èœæ§ããããŸãããã®çµæãåçµçæ³ã«äœ¿çšãããã¬ã¹ã®å®å šæ§ã«å¯Ÿããæžå¿µã«ãããäºæ¥ã®æ¡å€§ãé ããå¯èœæ§ããããŸãã
åçµçæ³ã¯å°ççã«ã¢ã¯ã»ã¹ãéåžžã«å¶éãããŠããŸãã¶Äæ¥Áެã¶Äã€ã³ãããªãŒã¹ãã©ãªã¢ãªã©ã®åœã ã§ã¯ã¶ÄæèÆÓçç·ŽããåŽååãäžè¶³ããŠãããããåŸºå Žã®çºå±ãèŠãããŸããã¶Ä±žž»ã«åç±³ãšãšãŒãããã«éå®ãããŠããŸã㱞Ÿµè¥²æ¶Ä§ã®é«ÆÓå€ç§æè¡ãããå®å šã§çã¿ãå°ãªãããšã蚌æãããŠããã«ããããããã¶Äå€ç§æ²»çÉ¡§é »ç¹ã«äœ¿çšãããŠããŸãã¶ÄÉ¡ãã«ãäºæž¬æéãéããŠã¶Äå¶Öçµçæ³ã®å®å šžä§ãšÁŽå¹žä§ã«é¢ããããå€ãã®ããŒã¿ã®å¿ 芞ä§ãšãè£ä»ÆÓããŒã¿ãªãã§ããã€ãã®çšéã§åçµçæ³ã䜿çšããããšã«ãããåŸºå Žã®æ¡å€§ã¯å¶çŽããããšäºæ³ãããŸãã¶Ä
ããã匚Ä÷ç ãç®èçŸÕò£ãªã©ã®å€ãã®å»åŠççŸæ£ã¯ã¶Äå¶Öçµçæ³ã䜿çšããŠæ²»çã§ããŸããççã¶Ääžå¿«æãçã¿ã¯ãäœã®äžéšã§ãÉ¡£ãŠãå šèº«ã§ãã£ãŠãÉ¡¶Äãã¹ãŠåçµçæ³ã§æ²»çÉ¡§ããŸãã¶Äå¶Öçµçæ³ã¯äŸµè¥²žä§ãäœããè¬ç©ã䜿çšããªãæ¶Ä§è³ªãããããã¶Ää»ã®å»åŠççŸæ£ãç æ°ã®æ²»çã«äœ¿çšã§ãããã©ããã確èªããããã«ããã«çү究ãé²ããããŠããŸãã
2017幎7æã«ç±³åœNIHåœç«å»åŠå³æžé€šïŒNIH/NLMïŒã§çºè¡šãããè«æãèµèè «çã®åçµæè¡ã®èšåºå®è·µã¬ã€ãã©ã€ã³ãã§ã¯ãåçµæè¡ã¯äŸµè¥²æ§ãäœããããå®å šã§ãåé¡ãå°ãªãããã®æšçåãæ¹åãããããšã瀺ãããŠãããåœåã®éããã®è峿·±ãè£å©çæ³ãå®å šã«çè§£ããã«ã¯ãããªãç ç©¶ãå¿ èŠã§ãããããªãç é¢ (ç±³åœ) ã«ã¯ãçµè žããããã³å°¿éããã®æ°ããæ²»çæ³ãæ¢æ±ããèšåºè©Šéšã宿œããå€ãã®ç ç©¶éšéããããŸãããã1ã€ã®æè¿ã®ç ç©¶ã§ã¯ã2017幎5æã®ãžã£ãŒãã«ãFrontiers in Physiologyãã«å ±åãããŠããããã«ãå šèº«åçµçæ³ïŒWBCïŒãéåéžæã«åœ±é¿ãäžããå¯èœæ§ã®ããããŸããŸãªççæ§çŸæ£ã®å¹æçãªæ²»çæ³ã§ããããšãããã³éååŸã®ååŸ©ãæ¹åããããšãçºèŠããŸããããããã£ãŠãWBC ã¯ãæå®³ãªåºæ¿ãšæŠãããšãã§ããæççããã³æé žåããªã¢åŒ·åæ²»çæ³ã§ãããšèããããŠããŸãã
äžçåžå Žã¯ãæ²»çã®çš®é¡ã«åºã¥ããŠåçµæè¡ãã¢ã€ã¹ããã¯çæ³ãããã³ãã£ã³ããŒçæ³ã«çްååãããŠããŸãã 2021 幎ãå·åæè¡ã«ããŽãªãŒãäžçåžå ŽããªãŒãããç·åçã®çŽ 55,00% ãå ããŸãããããã¯ãå€ç§çæ²»çã®éèŠãäžççã«å¢å ããŠããããšãåå ã§ããå¯èœæ§ããããŸãããã®æ²»çæ³ã¯åŸæ¥ã®æ²»çæ³ã«æ¯ã¹ãŠå¯äœçšãå°ãªããããããæ©ãå埩ããŸããããã«ãæŸå°ç·çæ³ãååŠçæ³ããã«ã¢ã³çæ³ãšäžŠè¡ããŠè£å®çæ³ãšããŠã䜿çšã§ããŸãã
çŸå®¹ãšãŠã§ã«ãã¹ããã£ãããã¹ãªã©ã®åéã§å¶Öçµçæ³ã®äœ¿çšãæ¡å€§ããŠããããã¶Äãã£ã³ããŒã»ã©ããŒã¯æãæ¶Ä¥é¶Äã«æé·ããÄþå Žã«ãªããšäºæ³ãããŠããŸãã宀å çæ³ã¯ã¢ã¹ãªãŒããã¹ããŒãéžæ×¹ã®éã§ãŸããŸã人æ°ãé«ÆÓŸã£ãŠããŸãã¶ÄÉ¡¹ããŒãå·å®³ã«å¯Ÿããå¶Öçµçæ³æ²»çÉ¡šãçÏâçãæå·ãšçã¿ãçÏâçã®çºçã®é ããªã©ãããŸããŸãªã¹ããŒãé¢é¶Ä£ã®è»¢åž°ãžã®åœ±é¿ã«é¢ããããã€ãã®çÒ¯ç©¶è«æãçºè¡šãããŠããŸããÉ¡ãã«ãç¹å®ã®çè矀ãé·æéÆËœ¿çšãããšãç¹ã«ã¹ããŒããÓÅã³ã®éã§çã¿ãçã¿ã¶Ä衰匱ã¶Äç²åŽãçããããšããããÉ¡ãŸãã
ãã£ãããã¹ã«ãããåçµçæ³ã®å©ç¹ã«é¢ããç¥èã®å¢å ãšããã£ãããã¹ ã¯ã©ãã§ã®åçµãã£ã³ããŒã®äœ¿çšéã®å¢å ã«ããããã£ãããã¹ ã¢ããªã±ãŒã·ã§ã³ ã»ã°ã¡ã³ã㯠2022 幎ãã 2030 幎ã®éã« 11.5% 以äžã®æé« CAGR ãèšé²ãããšäºæ³ãããŠããŸããäœã®èªç¶æ²»çããã»ã¹ã匷åããããè¿ éã«çã¿ã軜æžããèœåã DOMS (é çºæ§çèç) ã¯ãé«åŒ·åºŠã®ãã¬ãŒãã³ã°åŸã®çèã®äžå¿«æã硬çŽãå§çãç¹åŸŽãšããŸããåçµçæ³ã¯ãDOMS ãããè¿ éã«è»œæžããããã«å©çšã§ããŸãããããã®èŠçŽ ã¯ããã£ãããã¹ ã»ã³ã¿ãŒã§ã®åçµçæ³ã®äœ¿çšã奚å±ããŸãã 2021 幎ã«ã¯ãå·èµå庫ãæå€§ã®åžå Žã·ã§ã¢ãå ããŸããã骚é«ç§»æ€ãäœå€å粟ãè垯è¡ãã³ã¯ãªã©ã«äœ¿çšãããå»çã«ãããŠéèŠãªåœ¹å²ãæãããŠããŸãã
è£œè¬æ¥çã®ã³ãŒã«ã ãã§ãŒã³ ããžã¹ãã£ã¯ã¹ã¯ãå·èµå庫ã®ãã 1 ã€ã®éèŠãªçšéã§ããã¯ã¯ãã³ã®ä¿ç®¡ãå»è¬åã®èŒžéã«ã掻çšãããŠããŸããããšãã°ããã¡ã€ã¶ãŒã補é ããæ°åã³ãããŠã€ã«ã¹ææçã¯ã¯ãã³ã¯ææ°ãã€ãã¹ïŒïŒåºŠã§å·èµä¿åããå¿ èŠãããããããã®èæ ®äºé ã«ããã2021 幎ã«ã¯å·èµä¿åãåžå Žã®å€§éšåãå ããŸãããããã«ãå·åå€ç§æè¡ã¯ãéå» 10 幎éã§è «çç§ãå¿èç ç§ãç®èç§ãªã©ã®å€ãã®èšºçç§ã§æã人æ°ã®ããæ²»çéžæè¢ã® 1 ã€ã«ãªããŸãããåçµçæ³ã¯ãç¶²èèœçްèè «ãåç«è ºãããç®èãããåå®®é žãããªã©ã®ããŸããŸãªè «çãæ²»çããããã«è «çåŠã§å©çšã§ããŸããåçµçæ³ã«ã¯ãååŠçæ³ããã«ã¢ã³çæ³ãæŸå°ç·çæ³ãªã©ã®ä»ã®æ²»çæ³ã®è£è¶³ãšããŠç¹°ãè¿ã䜿çšã§ãããšãã倧ããªå©ç¹ããããŸãã
äžçåžå Žã¯ãç é¢ãå°é蚺çæãåçµçæ³æœèšãã¹ãããã£ãããã¹ ã»ã³ã¿ãŒãªã©ã«åãããŠããŸããç é¢ããã³å°éã¯ãªããã¯ã®ãšã³ããŠãŒã¶ãŒã»ã°ã¡ã³ãã¯ãäºæž¬æéãéã㊠8.1% ãšæãé«ãæé·çã瀺ãããšãäºæ³ãããŸããç é¢ãå°é蚺çæã«ãããåçµæè¡ããã³é¢é£ååã®éèŠã®å¢å ã¯ãããŸããŸãªç æ°ãéå®³ã®æ²»çã®ããã®åçµçæ³æè¡ã®é²æ©ã®çµæã§ããå€ãã®ç é¢ã蚺çæãåçµçæ³ããŒã¹ã®æ²»çãæäŸãå§ããŸããã
äºæž¬æéãéããŠãåçµçæ³ã»ã³ã¿ãŒã®éšéã¯å©çãããããæé·ãéãããšäºæ³ãããŸãããã®åéã®éçºã®å¢å ã¯ãäž»èŠåžå Žã«ãããåçµçæ³æœèšã®æ¡å€§ã«èµ·å ããŠããå¯èœæ§ããããŸããããšãã°ã2021 幎 10 æã«ãCARE Innovative Options ã¯ãèé¢é£ã®æ²»çã«ã³ã³ãã¥ãŒã¿ãŒå¶åŸ¡ã®åçµçæ³ãœãªã¥ãŒã·ã§ã³ãæäŸãã Slynarski Knee Clinic ã®å°å ¥ãçºè¡šããŸããã
ã¹ãããã³ãã£ãããã¹æœèšã»ã°ã¡ã³ãã¯ã2022 幎ãã 2030 幎ã®éã«æãé«ã CAGR ãæã€ãšäºæž¬ãããŠããŸããåçµçæ³ã¯ã倧ããªå©ç¹ãæã€æ°ãããã£ãããã¹ããã³ãŠã§ã«ãã¹ã®ãã¬ã³ãã§ãããã®çµæããã®ãµãŒãã¹ãéžæããåäººã®æ°ãå¢å ããé«ãéèŠãçããŠããŸããããã€ãã®ãã£ãããã¹ ã¯ã©ãããã«ã¹ ã¹ãã§ã¯ããã®å¯èœæ§ã掻çšããããã«åçµçæ³ãå°å ¥ããŠããŸããã¯ã©ã€ãªãµãŠããªã©ã®å¯å·çæ³è£ 眮ã¯ããã®ãã¶ã€ã³ãšæ©èœããã£ãããã¹æœèšãšäºææ§ãããããããã®åžå Žã»ã°ã¡ã³ãã§é«ãéèŠãèŠèŸŒãŸããŠããŸããããããã¹ãŠã®èŠå ã¯ãäºæž¬æéãéããŠåžå Žã®æ¡å€§ãåºæ¿ãããšäºæ³ãããŸãã
ã¯ã©ã€ãªãã£ã³ããŒã¯ãäºæž¬æéäžã« 10.0 ããŒã»ã³ããè¶ ãã CAGR ã§çºå±ãããšäºæ³ãããŸããããã¯ãåçµçæ³ã»ã³ã¿ãŒã®æ°ãå¢å ããçŸå®¹ã¯ãªããã¯ããã£ãããã¹ ã»ã³ã¿ãŒã§åºãåãå ¥ããããŠãããããšèããããŸããã¯ã©ã€ãªãã£ã³ããŒã¯ãã¹ããŒããã¬ãŒãã³ã°æœèšãã¹ããçŸå®¹ããªãŒãã¡ã³ãã«é©çšã§ããŸãã NCBI ã®ç ç©¶èšäºã«ãããšãã¯ã©ã€ãªãã£ã³ããŒãšã¯ã©ã€ãªãµãŠãã®å©ç¹ã«ã¯ãçã¿ã®è»œæžãšçèã®ä¿®åŸ©ãäœéæžå°ãççã®è»œæžãèªç¥çã®äºé²ã湿ç¹ã®çç¶ã®æ²»çãªã©ãå«ãŸããŸããããã«ãããããããããã€ãã®ç ç©¶ã¯æ²»çã®äž»åŒµã«ççŸããŠããŸãã Cochrane Review ã«ãããšãå ¬è¡šããã 4 ä»¶ã®è©Šéšã§ã¯ãçèã®äžå¿«æã®ç®¡çã«ãããåçµçæ³ã®å®è³ªçãªå©ç¹ã¯èŠåºãããŸããã§ããã
2021 幎ããã¯ã©ã€ãªã¬ã³ã¯å€§ããªåžå Žã·ã§ã¢ãç²åŸããŸãããã¯ã©ã€ãªã¬ã³ã¯ãç®èçŸæ£ãè «ççŸæ£ãªã©ãããŸããŸãªç æ°ã®æ²»çã«äœ¿çšãããŸãã䟵襲æ§ãäœããäžå¿«æã倱è¡ãå°ãªããããåŸæ¥ã®æè¡ãããã¯ããã«äŸ¿å©ã§å¿«é©ã§ããããã«ãã¯ã©ã€ãªã¬ã³ã¯ãç®èçŸæ£ãããçŸæ£ãªã©ãããŸããŸãªå»åŠçåé¡ã®æ²»çã«ã䜿çšãããŠããŸããã¯ã©ã€ãªã¬ã³ã¯ãå°åžžæ§ç£èŽ ãç£èŽ ãç®èè§ãç®èç å€ãç®èç·ç¶è «ãçŒçŒçžç å€ãçæ žãè¥åæ§ç¢çãã±ãã€ããããã³ã¹ãã³ã¿ãã°ã®æ²»çã«æãé »ç¹ã«äœ¿çšãããŸããããã«ãåå®®é žããã®æ²»çã«ã䜿çšãããŸããä»åŸæ°å¹Žéãã¯ã©ã€ãªã¬ã³ã®åžå Žã¯ãããã®èŠå ã«ãã£ãŠåããããå¯èœæ§ããããŸãã
Äþå Žã¯å°åããšã«åç±³ããšãŒããããã¢ãžã¢å€ªå¹³æŽã¶ÄLŽ¡²Ñ·¡Ž¡ã«åå²ãããŠããŸãã¶Ä
2018幎ã«ã¯åç±³ãåžå Žã§æå€§ã®ã·ã§ã¢ãå ããŠãããäºæž¬æéäžããã®å°äœãç¶æãããšäºæ³ãããŸããåç±³ã«ãããåçµçæ³åžå Žã®æé·ã¯ãåçµçæ³ã®äººæ°ã®é«ãŸããããã®çºççã®å¢å ãã¹ããŒããèº«äœæŽ»åã«é¢é£ããå·å®³ã®çºççã®å¢å ãå¿è¡ç®¡çŸæ£ã®çºççã®å¢å ãªã©ãå€ãã®èŠå ã«ãã£ãŠæšé²ãããŠããŸãã ãç±³åœã§ã¯æè¿ãã¢ã¹ãªãŒãã ãã§ãªããã£ãããã¹ãçŸå®¹ã«é¢å¿ã®ãã人ã ã®éã§åçµçæ³ã®äººæ°ãé«ãŸã£ãŠããŸãããã®çµæãå€ãã®å°éè·ã倧åŠã®èšç·Žéšéãããããã®æœèšã«ã¯ã©ã€ãªãµãŠãæ©æ¢°ãèšçœ®ãå§ããŠããŸããããã«ãã«ããçåäŒã¯ãããŸããŸãªçæ§çŸæ£ã«å¯Ÿããå®è¡å¯èœãªæ²»çéžæè¢ãšããŠå·åæè¡ãšå·åã¢ãã¬ãŒã·ã§ã³ã®å©çšãæå±ããŠããŸãã
欧å·åžå Žã¯ããã®å°åå ã§ã®æ°ããå¯å·çæ³è£œåã®æ¯æãšå°å ¥ã«ãããäžçåžå Žã®ããªãã®éšåãå ãããšäºæ³ãããŠããŸããããšãã°ã欧å·ã®ä¿å¥åœå±ã¯ãæç¶æ§æ°ç®¡æ¯çã䌎ã COPD æ£è ã®æ²»çã« CSA Medical ã®åçµçæ³èšç»ã䜿çšããããšãæ¿èªããŸããã
ã¢ãžã¢å€ªå¹³æŽå°åÑÌã¯æãå€§å¹ ãªæ¡å€§ãèŠèŸŒãŸããŠããŸããäžåœãã€ã³ããªã©ã®çºå±éäžåœã«ã¯ããªãã®èŠæš¡ã®å¯Ÿè±¡è ãååšããããšããŸããããã®åœã§ã®åçµçæ³æ©åšã®å©çšå¯èœæ§ã確ä¿ããããã®å€§æäŒæ¥ã«ããåªåã®å¢å ãããã®åºããã®å¢å ã«é¢ä¿ããŠããã